Patents by Inventor Natalia ARENAS-RAMIREZ

Natalia ARENAS-RAMIREZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 11851484
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 26, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20210246200
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: December 17, 2020
    Publication date: August 12, 2021
    Applicants: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2
    Publication number: 20210230269
    Abstract: The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
    Type: Application
    Filed: December 22, 2020
    Publication date: July 29, 2021
    Applicant: Universität Zürich
    Inventors: Onur Boyman, Natalia Arenas-Ramirez, Chao Zou
  • Immune-stimulating monoclonal antibodies against human interleukin-2
    Patent number: 10894828
    Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 19, 2021
    Assignee: Universität Zürich
    Inventors: Onur Boyman, Natalia Arenas-Ramirez, Chao Zou
  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 10889643
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: January 12, 2021
    Assignee: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20190016797
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 17, 2019
    Applicants: Novartis AG, Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • COMBINATION THERAPY COMPRISING A SUPERAGONISTIC ANTIBODY AGAINST INTERLEUKIN-2 AND A CHECKPOINT BLOCKADE AGENT
    Publication number: 20190016796
    Abstract: The invention relates to a combination medicament comprising a human interleukin-2 (hIL-2)-specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25, and an immune checkpoint inhibitor agent. The hIL-2 antibody can be given without or with recombinant hIL-2 and is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 17, 2019
    Applicant: UNIVERSITAT ZURICH
    Inventors: Onur BOYMAN, Natalia ARENAS-RAMIREZ